Patient-level adverse-event frequency may not reflect exposure-adjusted IVIG risk

Clicks: 20
ID: 330821
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #125 of 245 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Adverse events during intravenous immunoglobulin treatment were analyzed at the patient level, although cumulative treatment exposure varied across dermatologic indications. I highlight that patient-level adverse-event frequencies may therefore not reflect exposure-adjusted IVIG risk and suggest that cycle-based or exposure-adjusted analyses could strengthen interpretation of the study’s safety findings.
Reference Key
openalex_W7215131178 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Fatih Kaplan
Are you one of these authors? Claim your profile
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag429
URL
https://doi.org/10.1093/ced/llag429
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.